370 likes | 565 Views
E N D
1. 1 ?????????????????? Jean-Louis Chiasson, M.D.
Professor of MedicineUniversité de Montréal
2. 2 ??????
3. 3 ????????(PPHG)
4. 4 ????????????? ??????????????????????
????????????????????
?????????:STOP-NIDDM ??
???????????:STOP-NIDDM ??
????????????????
5. 5 ????????????? ????????????????????????.
??????????????????????.
?????????:STOP-NIDDM ??.
???????????:STOP-NIDDM ??.
????????????????
6. 6 ?????????????????????????????
7. 7 ?????????????????
8. 8 ???????????
9. 9 2-hPG????????????? - DECODE
10. 10 2-hPG ???????????????: DECODA
11. 11 ???????????IGT????2?????????????????????????
??????????????????????????????????2?????????????????????????
12. 12 ????????????? ????????????????????????
??????????????????????
?????????:STOP-NIDDM ??
???????????:STOP-NIDDM ??
????????????????
13. 13 ??????????????
14. 14 ??????2???????Cochrane ????
15. 15 ???????????????
16. 16 “?????,????”?????????????
17. 17 ????????a-????????,????????????
??????????????????? ???????,??????????????
????????????“?????, ????”?????????????
????????????
18. 18 ????????????? ????????????????????????
??????????????????????
?????????:STOP-NIDDM ??
???????????:STOP-NIDDM ??
???????????????
19. 19
20. 20 ???????:??????????IGT???????????(n = 321)
21. 21 Fig. 14.2/1.10A_1400Fig. 14.2/1.10A_1400
22. 22 ?????????????BMI?IGT???????????: STOP-NIDDM ??
23. 23 ??????????????????IGT???????????? 83%
STOP-NIDDM????????IGT??????????????????:
IGT???????????36%
?????????IGT???NGT
24. 24 ????????????? ????????????????????????
??????????????????????
?????????:STOP-NIDDM ??
???????????:STOP-NIDDM ??
????????????????
25. 25
26. 26 ?????IGT???????????The STOP-NIDDM Trial
27. 27 ?????IGT????????????????: STOP-NIDDM ??
28. 28 Fig. 14.2/1.10A_1400Fig. 14.2/1.10A_1400
29. 29
30. 30 ?????IGT?????????(IMT)????? STOP-NIDDM?????(n = 115)
31. 31 STOP-NIDDM???????IGT??????????????????:
???????????35% ;
???????????49% ;
??????????????50%.
Hanefeld ??????2????????:
PPG?CIMT?????????
??????????????????35%
32. 32 ????????????? ????????????????????????
??????????????????????
?????????:STOP-NIDDM ??
???????????:STOP-NIDDM ??
????????????????
33. 33
34. 34
35. 35 Experimental and clinical evidence indicates that both postprandial hyperglycemia is accompanied by oxidative stress, which in turn causes endothelial dysfunction and eventually atherosclerosis. Rapid increases in glucose and lipid levels after ingestion of a meal are also likely to trigger carbonyl stress which, either independently or by potentiation of oxidative stress, contributes to the development of both microvascular and macrovascular complications. PPG can trigger free radical production and therefore may contribute to the development of complications. Therefore, controlling PPG is an important part of the strategy for the prevention and management of complications in patients with type 2 diabetes.Experimental and clinical evidence indicates that both postprandial hyperglycemia is accompanied by oxidative stress, which in turn causes endothelial dysfunction and eventually atherosclerosis. Rapid increases in glucose and lipid levels after ingestion of a meal are also likely to trigger carbonyl stress which, either independently or by potentiation of oxidative stress, contributes to the development of both microvascular and macrovascular complications. PPG can trigger free radical production and therefore may contribute to the development of complications. Therefore, controlling PPG is an important part of the strategy for the prevention and management of complications in patients with type 2 diabetes.
36. 36 ??????????
IGT???????
IGT????????????????
IGT??????????????????
?????????????????????????????,????????????,??????????????
37. 37 IDF ???????????